Simvastatin Suppresses Tumor Growth of Head and Neck Squamous Cell Carcinoma ex vivo

Matthäus Stöhr, Christian Mozet, Kamelia Dimitrova, Andreas Dietz & Gunnar Wichmann
Introduction: Simvastatin (Sim) is approved as lipid-controlling drug in patients with cardiovascular risk to reduce hypercholesterolemia by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. However, recent publications suggest that Sim exerts an impact on tumor development and hence[for full text, please go to the a.m. URL]